A novel ALK-2 inhibitor, INCB000928, is currently assessed in a phase 1/2 trial in patients with myelodysplastic syndrome or MM who are transfusion-dependent or have symptomatic anemia (NCT04582539). This evidence concerns the gene ACVR1 and anemia (phenotype).